Platelet mass cytometry reveals dysregulation of prothrombotic pathways in essential thrombocythemia
Veronika Dill Kilian Kirmes Jiaying Han Melissa Klug Marc Rosenbaum Giacomo Viggiani Moritz von Scheidt Markus List Peter Herhaus Jürgen Ruland Florian Bassermann Karl-Ludwig Laugwitz Katharina S. Götze Philipp J. Jost Stefanie Jilg Conor J. Bloxham Philip W.J. Raake Isabell Bernlochner Dario Bongiovanni 1 Department of Internal Medicine III,School of Medicine,University Hospital rechts der Isar,Munich,Germany2 German Cancer Consortium (DKTK),Partner site Munich,Munich,Germany3 German Cancer Research Center (DKFZ),Heidelberg,Germany4 Department of Internal Medicine I,School of Medicine,University Hospital rechts der Isar,Munich,Germany5 German Center for Cardiovascular Research (DZHK),Partner site Munich Heart Alliance,Munich,Germany6 Experimental Bioinformatics,TUM School of Life Sciences Weihenstephan,Technical University of Munich,Munich,Germany7 School of Medicine,Institute of Clinical Chemistry and Pathobiochemistry,Technical University of Munich,Munich,Germany8 TranslaTUM,Center for Translational Cancer Research,Technical University of Munich,Munich,Germany9 Department of Cardiology,Deutsches Herzzentrum München,Technical University of Munich,Munich,Germany10 Clinical Department of Oncology,Medical University of Graz,Graz,Austria11 Onkologie Erding,Erding,Germany12 Department of Internal Medicine I,Cardiology,University Hospital Augsburg,University of Augsburg,Augsburg,Germany13 Department of Cardiovascular Medicine,Humanitas Clinical and Research Center IRCCS and Humanitas University,Rozzano,Milan,Italy
DOI: https://doi.org/10.1080/09537104.2024.2358244
2024-06-08
Platelets
Abstract:Thromboembolic events are common in patients with essential thrombocythemia (ET). However, the pathophysiological mechanisms underlying the increased thrombotic risk remain to be determined. Here, we perform the first phenotypical characterization of platelet expression using single-cell mass cytometry in six ET patients and six age- and sex-matched healthy individuals. A large panel of 18 transmembrane regulators of platelet function and activation were analyzed, at baseline and after ex-vivo stimulation with thrombin receptor-activating peptide (TRAP). We detected a significant overexpression of the activation marker CD62P (p-Selectin) ( p = .049) and the collagen receptor GPVI ( p = .044) in non-stimulated ET platelets. In contrast, ET platelets had a lower expression of the integrin subunits of the fibrinogen receptor GPIIb/IIIa CD41 ( p = .036) and CD61 ( p = .044) and of the von Willebrand factor receptor CD42b ( p = .044). Using the FlowSOM algorithm, we identified 2 subclusters of ET platelets with a prothrombotic expression profile, one of them (cluster 3) significantly overrepresented in ET (22.13% of the total platelets in ET, 2.94% in controls, p = .035). Platelet counts were significantly increased in ET compared to controls ( p = .0123). In ET, MPV inversely correlated with platelet count ( r =-0.96). These data highlight the prothrombotic phenotype of ET and postulate GPVI as a potential target to prevent thrombosis in these patients. Essential thrombocythemia (ET) is a rare disease characterized by an increased number of platelets in the blood. As a complication, many of these patients develop a blood clot, which can be life-threatening. So far, the reason behind the higher risk of blood clots is unclear. In this study, we analyzed platelet surface markers that play a critical role in platelet function and platelet activation using a modern technology called mass cytometry. For this purpose, blood samples from 6 patients with ET and 6 healthy control individuals were analyzed. We found significant differences between ET platelets and healthy platelets. ET platelets had higher expression levels of p-Selectin (CD62P), a key marker of platelet activation, and of the collagen receptor GPVI, which is important for clot formation. These results may be driven by a specific platelet subcluster overrepresented in ET. Other surface markers, such as the fibrinogen receptor GPIIb/IIIa CD41, CD61, and the von Willebrand factor receptor CD42b, were lower expressed in ET platelets. When ET platelets were treated with the clotting factor thrombin (thrombin receptor-activating peptide, TRAP), we found a differential response in platelet activation compared to healthy platelets. In conclusion, our results show an increased activation and clotting potential of ET platelets. The platelet surface protein GPVI may be a potential drug target to prevent abnormal blood clotting in ET patients.
cell biology,hematology